These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31691354)

  • 41. Tacrolimus Trough Level at the First Month May Predict Renal Transplantation Outcomes Among Living Chinese Kidney Transplant Patients: A Propensity Score-Matched Analysis.
    Yin S; Song T; Jiang Y; Li X; Fan Y; Lin T
    Ther Drug Monit; 2019 Jun; 41(3):308-316. PubMed ID: 31083041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
    Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.
    Staatz C; Taylor P; Tett S
    Nephrol Dial Transplant; 2001 Sep; 16(9):1905-9. PubMed ID: 11522877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.
    Sukkha S; Suansanae T; Iamrahong P; Wiwattanathum P
    Transplant Proc; 2020 Apr; 52(3):775-779. PubMed ID: 32143870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
    Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.
    Busque S; Cantarovich M; Mulgaonkar S; Gaston R; Gaber AO; Mayo PR; Ling S; Huizinga RB; Meier-Kriesche HU;
    Am J Transplant; 2011 Dec; 11(12):2675-84. PubMed ID: 21943027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
    O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
    J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection.
    O'Seaghdha CM; McQuillan R; Moran AM; Lavin P; Dorman A; O'Kelly P; Mohan DM; Little P; Hickey DP; Conlon PJ
    Clin Transplant; 2009; 23(4):462-8. PubMed ID: 19681975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.
    Plischke M; Riegersperger M; Dunkler D; Heinze G; Kikić Ž; Winkelmayer WC; Sunder-Plassmann G
    PLoS One; 2015; 10(8):e0135674. PubMed ID: 26270340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
    Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
    Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
    Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen.
    Meçule A; Tinti F; Bachetoni A; Poli L; D'Alessandro M; Alessandri C; Umbro I; Nofroni I; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1017-9. PubMed ID: 21620040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.